STOCK TITAN

UNITED HEALTH PRODUTS (UEEC) Financials

UEEC OTC
FY2025 annual
Revenue $0 n/m YoY
Net Income Not reported for FY2025
EPS (Diluted) -$0.01 n/m YoY
Operating Cash Flow -$1.2M n/m YoY
Market Cap $7.9M as of Oct 26, 2026
Price / Sales n/m revenue is not positive, FY2025
Price / Earnings n/m no net income reported
Price / Book n/m negative shareholder equity, so no book multiple, Q2 FY2026

A multiple compares the market's price with a filed figure; it says what the market pays, not how the business is doing. The market capitalization is the vendor's as of Oct 26, 2026; every other figure is from the SEC filings on this page. Not financial advice.

Source SEC Filings (10-K/10-Q) Latest period Q2 FY2026, ended Jun 30, 2026 Reported Currency USD FYE December

Newest figures come from the 10-Q for Q2 FY2026, filed Aug 14, 2026. Each column of the statement tables below links to the filing it was taken from, and every filing is listed on the UEEC SEC filings page.

UNITED HEALTH PRODUTS INC (UEEC) reported $0 in revenue for fiscal year 2025. This page shows its income statement, balance sheet, cash flow statement, and key financial ratios. View 15 years of annual fundamentals and quarterly data, with year-over-year growth rates and compound annual growth rates (CAGR). All figures are derived from SEC filings (10-K and 10-Q reports).

Rhea AI UEEC FY2025

The latest statements describe a cash-consuming business whose obligations expanded faster than its assets, leaving operations dependent on financing.

In FY2025, operating cash flow was -$1.2M while financing supplied $1.1M, so reported cash activity was funded largely outside operations rather than by internally generated cash. Meanwhile, liabilities rose 58.5% from FY2024 while assets rose 17.3%, making the balance-sheet deterioration broader than the cash-flow shortfall alone.

Short-term coverage is exceptionally thin: FY2025 current assets of $105.4K sat against current liabilities of $4.1M, producing a current ratio of 0.0x. The reported liquidity comparison was 0.7 months of latest annual operating outflow, leaving little working-capital cushion in the reported figures.

The spending profile also shifted: R&D fell 24.2% from FY2024 to $269.9K, while interest expense rose 250.5% to $113.3K. That combination means less reported development spending coincided with a heavier financing-cost burden, not a move toward operating self-funding.

[ NOT FINANCIAL ADVICE ]

Financial Health Signals

Financial health score not available

UNITED HEALTH PRODUTS INC does not currently provide enough eligible data for a peer-relative financial health score, so none is published. The signals and metrics below are current.

Piotroski F-Score Partial
1/5

UNITED HEALTH PRODUTS INC passes 1 of 5 computable financial strength tests (4 of the nine could not be computed from available data). No profitability signals pass, 1 of 3 leverage/liquidity signals pass, the one computable operating efficiency signal (asset turnover improving) does not pass.

Key Financial Metrics

Export CSV

Earnings & Revenue

Revenue
$0
YoYn/m
QoQn/m

UNITED HEALTH PRODUTS INC generated $0 in revenue in Q2 2026. The change from the same quarter a year earlier is not meaningful, because that figure was zero or negative. The change from the prior quarter is not meaningful, because that quarter’s figure was zero or negative.

EBITDA
-$166K
YoYn/m
QoQn/m

UNITED HEALTH PRODUTS INC's EBITDA was -$166K in Q2 2026, measuring earnings before interest, taxes, depreciation, and amortization. The change from the same quarter a year earlier is not meaningful, because that figure was zero or negative. The change from the prior quarter is not meaningful, because that quarter’s figure was zero or negative.

Net Income
-$284K
YoYn/m
QoQn/m

UNITED HEALTH PRODUTS INC reported a net loss of $284K in Q2 2026. The change from the same quarter a year earlier is not meaningful, because that figure was zero or negative. The change from the prior quarter is not meaningful, because that quarter’s figure was zero or negative.

EPS (Diluted)
$0.00
YoYn/m
QoQn/m

UNITED HEALTH PRODUTS INC earned $0.00 per diluted share (EPS) in Q2 2026. The change from the same quarter a year earlier is not meaningful, because that figure was zero or negative. The change from the prior quarter is not meaningful, because that quarter’s figure was zero or negative.

Cash & Balance Sheet

Cash & Debt
$24K
YoY+10786.7%
QoQ+2280.5%
5Y CAGR+6.9%

UNITED HEALTH PRODUTS INC held $24K in cash as of Q2 2026; no long-term debt figure is on record for that period.

Shares Outstanding
263M
YoY+1.9%
QoQ+1.5%
5Y CAGR+3.0%
10Y CAGR+5.6%

UNITED HEALTH PRODUTS INC had 263M shares outstanding in Q2 2026. This represents an increase of 1.9% from the same quarter a year earlier. Against the prior quarter it is up 1.5%.

Free Cash Flow

Not reported for Q2 2026.

Dividends Per Share

Not reported for Q2 2026.

Margins & Returns

None of these metrics is reported for Q2 2026.

Capital Allocation

R&D Spending
$4K
YoY-95.2%
QoQ-69.3%

UNITED HEALTH PRODUTS INC invested $4K in research and development in Q2 2026. This represents a decrease of 95.2% from the same quarter a year earlier. Against the prior quarter it is down 69.3%.

Share Buybacks

Not reported for Q2 2026.

Capital Expenditures

Not reported for Q2 2026.

UEEC Income Statement

Figures in USD, abbreviated K (thousand), M (million), B (billion), T (trillion). Negative values carry a minus sign and red type. Each change compares the year with the year before it, and each quarter with the same quarter a year earlier.

UEEC quarterly income statement
MetricQ2'2610-QQ1'2610-QQ4'2510-QQ3'2510-QQ2'2510-QQ1'2510-QQ4'24POS AMQ3'2410-Q
Revenue$0n/m$0n/mN/A$0n/m$0n/m$0n/mN/A$0n/m
R&D Expenses$4K-95.2%$13K-89.2%N/A$25K-61.5%$81K+23.2%$116K+0.6%N/A$66K-45.9%
SG&A Expenses$163K-13.0%$253KN/A$208K-36.2%$187K-44.8%N/AN/A$326K-0.8%
Operating Income-$167Kn/m-$266KN/A-$233Kn/m-$268Kn/mN/AN/A-$392Kn/m
EBITDA-$166Kn/m-$265KN/A-$232Kn/m-$267Kn/mN/AN/A-$391Kn/m
Interest Expense$48K+92.1%$48K+132.3%N/A$31K+303.0%$25K+229.7%$21K+172.1%N/A$8K-6.4%
Net Income-$284Kn/m-$316KN/A-$286Kn/m-$315Kn/mN/AN/A-$304Kn/m
EPS (Diluted)$0.00n/m$0.00n/m$0.00n/m$0.00n/m$0.00n/m-$0.01n/m-$0.01$0.00n/m
Diluted Shares (Avg)260M+1.1%259M+1.6%N/A258M+3.7%257M+3.8%255M+3.6%N/A249M+3.0%

Not reported in any period shown, so not listed: Cost of Revenue, Gross Profit, Income Tax, EPS (Basic).

UEEC Balance Sheet

Figures in USD, abbreviated K (thousand), M (million), B (billion), T (trillion). Negative values carry a minus sign and red type. Each change compares the year with the year before it, and each quarter with the same quarter a year earlier.

UEEC quarterly balance sheet
MetricQ2'2610-QQ1'2610-QQ4'2510-QQ3'2510-QQ2'2510-QQ1'2510-QQ4'24POS AMQ3'2410-Q
Total Assets$248K+204.1%$249K+138.0%$317K+17.3%$94K-37.4%$82K-33.0%$105K-55.2%$270K-5.2%$151K-55.1%
Current Assets$65K+206.3%$47K+34.5%$105K-45.0%$43K-32.3%$21K-19.7%$35K-72.9%$192K+26.3%$64K-53.9%
Cash & Equivalents$24K+10786.7%$1K-79.1%$65K-61.4%$18K-58.0%$225-98.8%$5K-93.9%$169K+77.0%$44K-40.9%
Short-Term Investments$0n/m$0n/m$0n/m$0n/m$0n/m$0n/m$0n/m$0n/m
InventoryN/AN/A$0n/mN/AN/AN/A$0-100.0%$0-100.0%
Long-Term Investments$0n/m$0n/m$0n/m$0n/m$0n/m$0n/m$0n/m$0n/m
Total Liabilities$4.7M+43.3%$4.5M+52.6%$4.3M+58.5%$3.4M+51.8%$3.3M+54.2%$3.0M+47.0%$2.7M+35.8%$2.3M+6.8%
Current Liabilities$4.2M+119.9%$4.2M+132.0%$4.1M+146.9%$2.0M-10.2%$1.9M-8.9%$1.8M-9.2%$1.6M-15.9%$2.2M+8.4%
Non-Current Liabilities$503K-63.3%$359K-69.5%$250K-76.7%$1.4M+5291.9%$1.4M+4016.6%$1.2M+2817.7%$1.1M+2112.2%$26K-52.2%
Long-Term DebtN/AN/A$0-100.0%$928K+518.3%$848K$648K$558Kn/m$150K
Total Equity-$4.4Mn/m-$4.3Mn/m-$4.0Mn/m-$3.3Mn/m-$3.2Mn/m-$2.9Mn/m-$2.5Mn/m-$2.1Mn/m
Retained Earnings-$82.1Mn/m-$81.7Mn/m-$81.5Mn/m-$80.8Mn/m-$80.5Mn/m-$80.2Mn/m-$78.7Mn/m-$77.9Mn/m

Not reported in any period shown, so not listed: Accounts Receivable, Goodwill.

UEEC Cash Flow Statement

Figures in USD, abbreviated K (thousand), M (million), B (billion), T (trillion). Negative values carry a minus sign and red type. Each change compares the year with the year before it, and each quarter with the same quarter a year earlier.

UEEC quarterly cash flow statement
MetricQ2'2610-QQ1'2610-QQ4'2510-QQ3'2510-QQ2'2510-QQ1'2510-QQ4'24POS AMQ3'2410-Q
Operating Cash Flow-$138Kn/m-$84Kn/m-$553Kn/m-$175Kn/m-$185Kn/m-$274Kn/m-$181Kn/m-$320Kn/m
Depreciation & Amortization$1K0.0%$1K0.0%$1K+0.1%$1K-0.1%$1K-0.1%$1K+0.1%$1K0.0%$1K0.0%
Investing Cash Flow$0n/m$0n/m$0n/m$0n/m$0n/m$0n/m$0n/m$0n/m
Financing Cash Flow$161K-10.3%$20K-81.7%$600K+95.7%$193K-43.9%$180K-20.2%$110K-71.9%$307K-48.7%$345K-36.8%

Not reported in any period shown, so not listed: Stock-Based Compensation, Capital Expenditures, Free Cash Flow, Dividends Paid, Share Buybacks.

UEEC Financial Ratios

Margins and returns are percentages; the remaining ratios are unitless multiples. Each change compares the year with the year before it, and each quarter with the same quarter a year earlier.

UEEC quarterly financial ratios
MetricQ2'2610-QQ1'2610-QQ4'2510-QQ3'2510-QQ2'2510-QQ1'2510-QQ4'24POS AMQ3'2410-Q
Return on Assets-114.6%+272.0pp-126.9%N/A-302.8%-101.2pp-386.6%-31.5ppN/AN/A-201.6%-56.9pp
Current Ratio0.020.0x0.010.0x0.03-0.1x0.020.0x0.010.0x0.020.0x0.120.0x0.030.0x
Asset Turnover0.000.0x0.000.0xN/A0.000.0x0.000.0x0.000.0xN/A0.000.0x

Not reported in any period shown, so not listed: Gross Margin, Operating Margin, Net Margin, Return on Equity, Debt-to-Equity, Liabilities-to-Equity, FCF Margin.

Note: Shareholder equity is negative (-$4.0M), which causes the debt-to-equity, liabilities-to-equity and return on equity ratios to appear negative or not meaningful. This can occur from accumulated losses or large share buyback programs.

Note: The current ratio is below 1.0 (0.03), indicating current liabilities exceed current assets, which may suggest potential short-term liquidity concerns.

Frequently Asked Questions

What is UNITED HEALTH PRODUTS INC's annual revenue?

UNITED HEALTH PRODUTS INC (UEEC) reported $0 in total revenue for fiscal year 2025. The change from the previous fiscal year is not meaningful, because that year’s figure was zero or negative. Revenue measures the total income earned from the company's primary business operations before any expenses are deducted.

What is UNITED HEALTH PRODUTS INC's earnings per share (EPS)?

UNITED HEALTH PRODUTS INC (UEEC) reported diluted earnings per share of -$0.01 for fiscal year 2025. The change from the previous fiscal year is not meaningful, because that year’s figure was zero or negative. EPS represents the portion of a company's net income allocated to each outstanding share of common stock and is widely used to evaluate profitability on a per-share basis.

How much debt does UNITED HEALTH PRODUTS INC have?

As of fiscal year 2025, UNITED HEALTH PRODUTS INC (UEEC) had $65K in cash and equivalents against $0 in long-term debt.

UNITED HEALTH PRODUTS INC (UEEC) recorded an outflow of $1.2M in operating cash flow during fiscal year 2025, representing cash used by core business activities.

UNITED HEALTH PRODUTS INC (UEEC) had $317K in total assets as of fiscal year 2025, including both current and long-term assets.

UNITED HEALTH PRODUTS INC (UEEC) invested $270K in research and development during fiscal year 2025.

UNITED HEALTH PRODUTS INC (UEEC) had 259M shares outstanding as of fiscal year 2025.

UNITED HEALTH PRODUTS INC (UEEC) had a current ratio of 0.03 as of fiscal year 2025, which is below 1.0, which may suggest potential liquidity concerns.

UNITED HEALTH PRODUTS INC (UEEC) has no price-to-earnings ratio at the moment: no net income reported. The market capitalization is $7.9M as of Oct 26, 2026; a multiple compares that price with a filed figure and says nothing about the quality of the business.

UNITED HEALTH PRODUTS INC (UEEC) has no price-to-sales ratio at the moment: revenue is not positive (FY2025). The market capitalization is $7.9M as of Oct 26, 2026; a multiple compares that price with a filed figure and says nothing about the quality of the business.

At the end of fiscal year 2025, UNITED HEALTH PRODUTS INC (UEEC) held $65K in cash, cash equivalents and investments, and reported an operating cash outflow of $1.2M over that year. Dividing the one by the other, the reported balance equals about 1 month of the outflow reported that year. This is arithmetic over figures already filed, not a projection: it assumes nothing about future spending, financing or operations.

UNITED HEALTH PRODUTS INC (UEEC) has negative shareholder equity of -$4.0M as of fiscal year 2025, so no debt-to-equity or liabilities-to-equity ratio is reported: dividing debt by equity that is not positive produces a number that cannot be read as leverage. This can occur when accumulated losses exceed invested capital, or after large share buyback programs. Other solvency metrics like the current ratio or interest coverage may be more informative.

UNITED HEALTH PRODUTS INC (UEEC) has a Piotroski F-Score of 1 out of 5 computable signals; 4 of the nine could not be computed from available data, so the full-scale strength rating is not shown. The F-Score evaluates nine binary signals across profitability (positive ROA, positive cash flow, improving ROA, earnings quality), leverage (decreasing debt, improving liquidity, no share dilution), and operating efficiency (improving gross margin, improving asset turnover). Scores of 7 to 9 indicate strong and improving fundamentals. Learn more in our complete guide to financial health indicators.

Back to top